This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Dec;24(12):1629-1631.

doi: 10.1007/s10147-019-01518-7. Epub 2019 Sep 3.

Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial

Atsushi Mizokami¹, Go Kimura², Yasuhisa Fujii³, Shiro Hinotsu⁴, Kouji Izumi⁵

Affiliations

Affiliations

¹ Department of Urology, Kanazawa University, Kanazawa, Japan. mizokami@staff.kanazawa-u.ac.jp.
² Department of Urology, Nippon Medical School, Tokyo, Japan.
³ Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan.
⁴ Department of Biostatistics and Clinical Epidemiology, Sapporo Medical University, Sapporo, Japan.
⁵ Department of Urology, Kanazawa University, Kanazawa, Japan.

PMID: 31482239
DOI: 10.1007/s10147-019-01518-7

Comment

Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial

Atsushi Mizokami et al. Int J Clin Oncol. 2019 Dec.

. 2019 Dec;24(12):1629-1631.

doi: 10.1007/s10147-019-01518-7. Epub 2019 Sep 3.

Authors

Atsushi Mizokami¹, Go Kimura², Yasuhisa Fujii³, Shiro Hinotsu⁴, Kouji Izumi⁵

Affiliations

¹ Department of Urology, Kanazawa University, Kanazawa, Japan. mizokami@staff.kanazawa-u.ac.jp.
² Department of Urology, Nippon Medical School, Tokyo, Japan.
³ Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan.
⁴ Department of Biostatistics and Clinical Epidemiology, Sapporo Medical University, Sapporo, Japan.
⁵ Department of Urology, Kanazawa University, Kanazawa, Japan.

PMID: 31482239
DOI: 10.1007/s10147-019-01518-7

No abstract available

PubMed Disclaimer

Comment on

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C. Smith M, et al. Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6. Lancet Oncol. 2019. PMID: 30738780 Clinical Trial.

References

1. J Clin Endocrinol Metab. 2010 Jul;95(7):3165-72 - PubMed
1. Lancet Oncol. 2019 Mar;20(3):408-419 - PubMed
1. Anticancer Res. 2010 Dec;30(12):5201-5 - PubMed
1. Eur Urol. 2016 Jun;69(6):1016-25 - PubMed
1. Clin Cancer Res. 2017 Aug 1;23(15):4335-4346 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information